SKYE SEC Filings: 8-K, 10-Q, S-3 & 424B – Skye Bioscience

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Skye Bioscience Announces CFO Resignation, CEO Appointment as Principal Financial Officer, and Nasdaq Compliance

Sep 11, 2026

8-K

Skye Bioscience Enters into $22 Million Equity Line of Credit (ELOC) Agreement with Redmile Group

Aug 24, 2026

8-K/A

Reverse Stock Split Effective August 24, 2026; Common Stock to Trade on Nasdaq Under Existing Ticker Symbol.

Aug 19, 2026

8-K

Skye Bioscience Receives Nasdaq Deficiency Notice Regarding Stockholders' Equity

Aug 18, 2026

8-K

Skye Bioscience and Redx Pharma Announce Merger to Form Fibrx Therapeutics with $125 Million in Financing

Aug 14, 2026

8-K

Skye Bioscience Transfers Listing to Nasdaq Capital Market

Jun 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 4,000,000

May 17, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 33,753,271 | Warrants amount: 2,325,537

Apr 10, 2024

424B3

Up to 140,694,163 Shares of Common Stock-

Nov 10, 2021

424B5

58,111,112 Shares of Common Stock-

Sep 28, 2021

424B3

Up to 140,694,163 Shares of Common Stock-

Aug 5, 2021

424B3

Up to 140,694,163 Shares of Common Stock-

May 7, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8